A randomized controlled study of interventional thrombus removal and drug therapy alone in the treatment of intermediate and high-risk pulmonary embolism

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055878

Enrollment

Unknown

Registered

2022-01-22

Start date

2022-01-22

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary embolism

Interventions

Control Group:Drugs

Experimental group:Interventional thrombus removal

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for medium- and high-risk pulmonary embolism in my country and internationally; 2. Aged 18 to 75 years; 3. Voluntarily participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Chronic pulmonary embolism; 2. Patients with left heart cardiovascular disease who cannot tolerate interventional therapy; 3. Patients with chronic kidney disease or renal insufficiency who cannot tolerate imaging examination; 4. Pregnant or lactating women; 5. Do not agree to join the clinical investigator.

Design outcomes

Primary

Measure	Time frame
Right heart function;	—

Secondary

Measure	Time frame
Symptoms;Vital signs;D dimer;	—

Countries

China

Contacts

Public ContactLi Jifeng

Beijing Chaoyang Hospital Affiliated to Capital Medical University

lijifeng@ccmu.edu.cn+86 13466746528

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026